Equities

Zota Health Care Ltd

Zota Health Care Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)563.50
  • Today's Change2.15 / 0.38%
  • Shares traded5.27k
  • 1 Year change+28.65%
  • Beta0.9313
Data delayed at least 15 minutes, as of Nov 14 2024 05:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Zota Health Care Ltd had net income fall 148.55% from a loss of 57.73m to a larger loss of 143.48m despite a 28.96% increase in revenues from 1.40bn to 1.80bn. An increase in the selling, general and administrative costs as a percentage of sales from 33.45% to 39.04% was a component in the falling net income despite rising revenues.
Gross margin49.86%
Net profit margin-12.23%
Operating margin-9.93%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Zota Health Care Ltd fell by 1.10m. Cash Flow from Financing totalled 187.76m or 10.40% of revenues. In addition the company used 59.84m for operations while cash used for investing totalled 129.03m.
Cash flow per share0.1799
Price/Cash flow per share3,270.20
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Zota Health Care Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -143.84%. Additionally, five year annualized dividend per share growth ranks below the industry average relative to its peers.
Div yield(5 year avg)0.42%
Div growth rate (5 year)0.00%
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-199.98
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.